CHICAGO STAR: T-Neuro Pharma to Presents Expanded Alzheimer’s Disease Blood Biomarker Assay at Clinical Trials on Alzheimer’s Disease (CTAD) conference
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that it will present new research on its T-Track blood biomarker assay for Alzheimer’s at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference. The poster presentation, scheduled for…
BIOSPACE: T-Neuro Pharma’s Trailblazing Alzheimer’s Research Receives Acclaim in PNAS Commentary
T-Neuro Pharma, a leading biotechnology research company dedicated to developing innovative therapies for neurodegenerative diseases, announced that its groundbreaking research on Alzheimer’s disease has been highlighted in a commentary published in the Proceedings of the National Academy of Sciences USA (PNAS), a peer-reviewed journal of…
BIZJOURNAL: Albuquerque biopharma startup eyes investment after research paper publishes
An Albuquerque biopharmaceutical startup hopes publishing a “remarkable” study on its approach to detecting and diagnosing Alzheimer’s disease can help the company attract more investment and reach commercial success. Read the Full Article
JOURNAL OF ALZHEIMER’S DISEASE: Can Immunity Impact Alzheimer’s Disease?
Evolutionary Selection of APOE 4 Encourages Increased Focus on Immunity in Alzheimer’s Disease By: Christopher J. Wheeler Abstract. Smith and Ashford present a compelling hypothesis on evolution of APOE alleles, namely that 4 prevalence is mediated by immune selection pressure against enteric pathogens. While the…